CRISM Therapeutics (CRTX) Competitors GBX 10.90 +1.40 (+14.74%) As of 03:22 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock CRTX vs. ARV, LND, VAST, CLA, CTL, GLR, CRTM, BZT, TGR, and BMVShould you be buying CRISM Therapeutics stock or one of its competitors? The main competitors of CRISM Therapeutics include Artemis Resources (ARV), Landore Resources (LND), Vast Resources (VAST), Celsius Resources (CLA), CleanTech Lithium (CTL), Galileo Resources (GLR), Critical Metals (CRTM), Bezant Resources (BZT), Tirupati Graphite (TGR), and Bluebird Merchant Ventures (BMV). These companies are all part of the "other industrial metals & mining" industry. CRISM Therapeutics vs. Its Competitors Artemis Resources Landore Resources Vast Resources Celsius Resources CleanTech Lithium Galileo Resources Critical Metals Bezant Resources Tirupati Graphite Bluebird Merchant Ventures Artemis Resources (LON:ARV) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Do insiders and institutionals have more ownership in ARV or CRTX? 5.2% of Artemis Resources shares are owned by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are owned by institutional investors. 13.0% of Artemis Resources shares are owned by company insiders. Comparatively, 97.3% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, ARV or CRTX? CRISM Therapeutics has lower revenue, but higher earnings than Artemis Resources. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Artemis Resources, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtemis Resources£634.57K20.32-£43.80M-£0.01-38.79CRISM Therapeutics£25K174.23-£792.20K-£0.02-605.56 Does the media prefer ARV or CRTX? In the previous week, Artemis Resources' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score. Company Overall Sentiment Artemis Resources Neutral CRISM Therapeutics Neutral Is ARV or CRTX more profitable? CRISM Therapeutics has a net margin of 0.00% compared to Artemis Resources' net margin of -6,902.37%. CRISM Therapeutics' return on equity of -13.12% beat Artemis Resources' return on equity.Company Net Margins Return on Equity Return on Assets Artemis Resources-6,902.37% -42.70% -1.79% CRISM Therapeutics N/A -13.12%-26.77% Which has more risk and volatility, ARV or CRTX? Artemis Resources has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, CRISM Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. SummaryCRISM Therapeutics beats Artemis Resources on 6 of the 11 factors compared between the two stocks. Get CRISM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON ExchangeMarket Cap£4.36M£1.00B£3.66B£2.56BDividend YieldN/A6.12%5.06%5.33%P/E Ratio-605.56123.29161.365,399.09Price / Sales174.2345,636.9217,824.8297,453.95Price / CashN/A24.7025.8927.93Price / Book0.258.696.769.13Net Income-£792.20K£71.69M£149.17M£5.89B7 Day Performance3.81%4.69%3.25%0.98%1 Month Performance5.83%16.19%12.40%3.00%1 Year Performance9.00%71.23%47.28%191.03% CRISM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCRISM TherapeuticsN/AGBX 10.90+14.7%N/A-20.0%£4.36M£25K-605.564Gap UpARVArtemis ResourcesN/AGBX 0.39+2.7%N/A-51.4%£14.76M£634.57K-33.19N/AGap UpHigh Trading VolumeLNDLandore ResourcesN/AGBX 3.92-3.3%N/A+50.8%£13.74MN/A-39,160.006Gap UpVASTVast ResourcesN/AGBX 0.34+1.8%N/A+336.8%£13.14M£446K-28.20350CLACelsius ResourcesN/AGBX 0.40flatN/A-38.3%£12.54M£647.00-67.80N/AGap UpCTLCleanTech LithiumN/AGBX 5.37+2.3%N/A-68.4%£10.50MN/A-559.3820Gap DownGLRGalileo ResourcesN/AGBX 0.87+2.4%N/A-12.3%£10.06MN/A580.001Positive NewsGap DownHigh Trading VolumeCRTMCritical MetalsN/AGBX 9.49+2.6%N/A+292.0%£9.03M£3.58K-24.313High Trading VolumeBZTBezant ResourcesN/AGBX 0.05-1.8%N/A+103.7%£8.74MN/A-540.005TGRTirupati GraphiteN/AN/AN/AN/A£8.67M£4.38M-2.4136,000BMVBluebird Merchant VenturesN/AGBX 1.08-1.8%N/A-1.2%£8.64MN/A-327.279 Related Companies and Tools Related Companies Artemis Resources Alternatives Landore Resources Alternatives Vast Resources Alternatives Celsius Resources Alternatives CleanTech Lithium Alternatives Galileo Resources Alternatives Critical Metals Alternatives Bezant Resources Alternatives Tirupati Graphite Alternatives Bluebird Merchant Ventures Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:CRTX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
